Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- AZ, BMKK Launch Once-Weekly GLP-1 Receptor Agonist Bydureon
May 20, 2013
- Takeda Slips to 3rd Place in 25 Major Pharmas’ Operating Profit Ranking
May 20, 2013
- Takeda’s Novel Diabetes Treatment GPR40 Shows Efficacy in Japanese Patients in PIII Trial
May 20, 2013
- New Rules on Settai Resulted in Fewer Serious Violations of Fair Competition Code in FY2012: Industry FTC
May 20, 2013
- 3 Major Generic-Only Makers Offer Mixed Views on Govt Promotion Measures
May 17, 2013
- FY2012 Sales Up 18% for Both Generic-Only Makers, Research-Driven Pharmas’ Generic Units; Govt Incentive Measures Biggest Contributor
May 17, 2013
- Toyama Chemical to License Novel Macrolide Agent from Cempra
May 17, 2013
- Yakult to File Elplat for New Indications of Pancreas and Gastric Cancer
May 17, 2013
- Astellas to File NDA for Enzalutamide in Japan in 1st Half of FY2013
May 17, 2013
- FY2012 Japan Pharma Market: Sales of Major Long-Listed Drugs Tumble 30-40%
May 16, 2013
- Astellas to Reorganize Research Functions, Shut Down US Subsidiaries
May 16, 2013
- Pres. Sagara Says Profit Increase Still Ways Away, Company to Invest to Enhance Pipeline: Ono
May 16, 2013
- PII Study of Terbinafine Patch for Tinea Unguium in US Shows No Significant Difference Against Placebo in Primary Endpoint: Hisamitsu
May 16, 2013
- Investigation on Ranbaxy Quality Issue Ends, Risks Eliminated: Daiichi Sankyo Pres.
May 15, 2013
- Eisai Forecasts 1st Sales Rise in 4 Years in FY2013, Business Slump to Bottom Out: Pres. Naito
May 15, 2013
- Otsuka Holdings’ Pharma Sales Up 8.8% in FY2012, Spurred by Upbeat Abilify
May 15, 2013
- Diabetes Treatment Market to Exceed 500 Billion Yen in 2017: Fuji-Keizai
May 15, 2013
- Eight Companies Initiate Voluntary Recall of Enalapril Generics Due to Deviations from Specifications
May 15, 2013
- Astellas’s FY2012 Sales Top 1 Trillion Yen; XTANDI Scores 12.2 Billion Yen in 1st Year
May 14, 2013
- Ono Sales Down 0.3% Despite New Product Sales Increase, Double-Digit Decline in Profits Due to Higher Cost to Sales Ratio
May 14, 2013
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…